The estimated Net Worth of Tausif Butt is at least $565 Tausend dollars as of 7 May 2021. Mr Butt owns over 10,870 units of ChemoCentryx Inc stock worth over $565,131 and over the last 4 years he sold CCXI stock worth over $0.
Mr has made over 1 trades of the ChemoCentryx Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,870 units of CCXI stock worth $120,222 on 7 May 2021.
The largest trade he's ever made was buying 10,870 units of ChemoCentryx Inc stock on 7 May 2021 worth over $120,222. On average, Mr trades about 2,174 units every 0 days since 2021. As of 7 May 2021 he still owns at least 10,870 units of ChemoCentryx Inc stock.
You can see the complete history of Mr Butt stock trades at the bottom of the page.
Tausif Butt is the Exec. VP & COO at ChemoCentryx Inc.
Mr Butt is 55, he's been the Exec. VP & COO of ChemoCentryx Inc since . There are 12 older and no younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
Tausif's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta und (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: